Session Abstract – PMWC 2019 Silicon Valley

Session Synopsis: Data-driven innovations are transforming every facet of our lives – most notably, healthcare and the life sciences. Big data and advanced analytics are powering the next great industrial revolution. The promise and potential are enormous: from novel medicines to better prediction of disease to selection of better interventions. Big data approaches have also been the subject of much hype and skepticism. This panel brings together leaders from biotech, venture capital, big data, AI and ML to debate the success, potential, and limitations of big data in providing solutions to some the biggest challenges facing us in healthcare today.

Session Chair Profile

M.D., Ph.D., Senior Partner, Takeda Ventures, Inc.
Biography

David’s career focus has been translating promising science into clinical impact. He trained as physician-scientist at Harvard and MIT, did his medicine and endocrinology training at MGH, and his post-doc in the Melton Lab at the Harvard Stem Cell Institute. He spent the following decade in and around pharma including several years in experimental medicine at Merck, several years at BCG, and several years at Theravance in South San Francisco. From 2014-2017, he was the Chief Medical Officer of the cloud genomics company, DNAnexus. David is passionate about the opportunities at the intersection of technology and health; at Takeda Ventures, which he joined as a Senior Partner in 2017, he is building out a data science and technology (DST) capability. David also writes about issues related to entrepreneurship, technology, innovation, and medicine, including occasional commentaries for WSJ, FT, WaPo, etc, and writes a regular blog at Forbes. Since 2015 he has co-hosted a twice-monthly podcast on tech & health, “Tech Tonics,” with Lisa Suennen.

Speaker Profile

M.D., MBA, VP and Head, Regeneron Genetics Center
Biography

Dr. Baras serves as Vice President, Regeneron Pharmaceuticals and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants. The RGC has produced many high impact discoveries identifying new drug targets (such as HSD17B13 in chronic liver diseases), validating existing development programs (Regeneron’s evinacumab program targeting ANGPTL3, REGN3500 targeting IL33, and many more), and contributing important new gene discoveries and precision medicine strategies. The RGC has sequenced more than 300,000 individuals to date, collaborating with more than 60 institutions around the world, and plans to sequence the genomes of millions of participants across its studies. Previously, Dr. Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody based therapeutics, cancer research, and nanotechnology applications in drug development. Dr. Baras received his Bachelor’s of Science, M.D., and M.B.A., all from Duke University.

Speaker Profile

MPH, M.D., Chief Medical Officer, Verily
Biography

Jessica L. Mega, MD, MPH, is the Chief Medical Officer at Verily Life Sciences. As a faculty member at Harvard Medical School (on leave), a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women’s Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. She also directed the TIMI Study Group’s Genetics Program. Her research findings have been published in the New England Journal of Medicine, Lancet, JAMA, and elsewhere. Dr. Mega is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).

Speaker Profile

Ph.D., Co-Founder, Chief Commercial Officer, EVP, GNS Healthcare
Biography

Dr. Iya Khalil is a technology entrepreneur and physicist with a vision of transforming medicine into a discipline that is quantitative, predictive, and patient-centric via big data analytic approaches. She co-founded two big data companies, Via Science and GNS Healthcare, and is the co-inventor of the proprietary computational engine that underpins both entities. Dr. Khalil’s expertise spans applications in drug discovery, drug development all the way to treatment algorithms that can be applied at the point of care. She is a frequent speaker at industry events and conferences and was recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine. She was named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry and was recognized for her ability to build bridges across the life science and healthcare industries, bringing people together to harness the power of predictive modeling to change the lives of patients. Dr. Khalil serves on the board of the Accelerated Cure Project and the Scientific Advisory Board of Biocentury Innovations. Recently, she was appointed to the Massachusetts Center for Health Information and Analysis (CHIA) Oversight Council by Governor Baker.

Speaker Profile

M.D., Chief Scientific Officer and Head of Research & Development, Gilead Sciences, Inc.
Biography

Dr. McHutchison joined Gilead in 2010, and was appointed Chief Scientific Officer in March 2018. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018, Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!